Cancers with TP53 alterations exhibited decreased levels of lipid glycerophosphocholines, tumors with ERBB2 amplification associated with changes in docosapentaenoate, fucose, and 1-oleoylglycerophosphoethanolamine levels, and PIK3CA mutations correlated with altered malonylcarnitine levels. This evidence concerns the gene ERBB2 and cancer.